{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-027200","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2026-06-04T12:00:39+00:00","discovered_at":"2026-06-04T12:05:00.305210+00:00","generated_at":"2026-06-04T12:06:35.794541+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Kairos Pharma signs term sheet to acquire CL-741, a Phase 1-ready c-MET inhibitor; outlines 2026 milestones","bullets":["Acquiring worldwide rights to CL-741, an oral type IIb c-MET kinase inhibitor targeting EGFR-mutated lung cancer and esophageal/gastric cancers.","CL-741 is Phase 1-ready; Phase 1 study initiation planned for H2 2026.","ENV-105 Phase 2 trial in prostate cancer continues; more trial sites expected by year-end.","ENV-105 Phase 1 in NSCLC results anticipated by Q3 2026.","Over $8M in non-dilutive funding; low monthly burn rate highlighted."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-027200","json":"https://secwatch.observer/filing/0001493152-26-027200.json","markdown":"https://secwatch.observer/filing/0001493152-26-027200.md","text":"https://secwatch.observer/filing/0001493152-26-027200.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000149315226027200/0001493152-26-027200-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000149315226027200/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T12:06:35.794541+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}